Peptide YY vs GLP-1 for satiety: Side Effects, Dosing, and Results Compared

Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

In the intricate dance of human physiology, the regulation of appetite and satiety plays a pivotal role in maintaining overall health and preventing metaboli...

# Peptide YY vs GLP-1 for Satiety: Side Effects, Dosing, and Results Compared

Opening Paragraph

In the intricate dance of human physiology, the regulation of appetite and satiety plays a pivotal role in maintaining overall health and preventing metabolic disorders such as obesity and type 2 diabetes. The sensation of satiety, or feeling full and satisfied after eating, is a complex process influenced by a myriad of hormonal signals originating from the gastrointestinal tract and brain. Among these crucial signals are Peptide YY (PYY) and Glucagon-Like Peptide-1 (GLP-1), two gut hormones that have garnered significant attention for their profound effects on appetite control and energy homeostasis. Understanding the distinct mechanisms, comparative efficacy, potential side effects, and appropriate dosing strategies for PYY and GLP-1 is paramount for individuals seeking effective interventions for weight management and metabolic health. This article will delve into a comprehensive comparison of these two powerful peptides, exploring their biological roles, how they influence hunger and fullness, and what current scientific evidence suggests regarding their therapeutic applications. The rising global prevalence of obesity underscores the urgent need for nuanced approaches to appetite regulation, making a detailed examination of PYY and GLP-1 not just academically interesting, but clinically vital for improving public health outcomes.

What Is Peptide YY (PYY)?

Peptide YY (PYY) is a 36-amino acid peptide hormone primarily released by L-cells in the ileum and colon in response to food intake. It belongs to the neuropeptide Y (NPY) family of peptides, which also includes NPY and pancreatic polypeptide (PP). PYY exists in two main endogenous forms: PYY1–36 and PYY3–36. The latter, PYY3–36, is the predominant circulating form and is generated from PYY1–36 by the enzyme di-peptidyl peptidase IV (DP-IV) [1]. PYY acts as an anorexigenic hormone, meaning it reduces appetite and promotes satiety. Its release is proportional to the caloric content of a meal, with levels typically rising within 15 minutes of eating, peaking 1-2 hours post-meal, and remaining elevated for several hours [2]. This sustained elevation contributes to the feeling of fullness and reduced food intake after a meal.

What Is Glucagon-Like Peptide-1 (GLP-1)?

Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone, also secreted by the L-cells of the small intestine, particularly in the ileum and colon, in response to nutrient ingestion. GLP-1 is derived from the proglucagon gene and plays a multifaceted role in glucose homeostasis and appetite regulation. Its primary functions include stimulating glucose-dependent insulin secretion from pancreatic beta-cells, suppressing glucagon secretion from alpha-cells, delaying gastric emptying, and promoting satiety [3]. The delay in gastric emptying contributes to a prolonged feeling of fullness, while its direct action on brain centers involved in appetite control further reduces food intake. GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic the effects of natural GLP-1 and are widely used in the treatment of type 2 diabetes and obesity.

How They Work: Mechanisms of Action

Both PYY and GLP-1 exert their anorexigenic effects through distinct yet sometimes overlapping pathways, primarily involving the brain and gastrointestinal tract.

PYY Mechanism of Action

PYY3–36 primarily acts on Y2 receptors located in various regions of the brain, particularly in the hypothalamic arcuate nucleus (ARC). The ARC contains two main neuronal populations involved in appetite regulation: pro-opiomelanocortin (POMC) neurons, which promote satiety, and neuropeptide Y (NPY)/Agouti-related peptide (AgRP) neurons, which stimulate appetite. PYY3–36 inhibits the activity of NPY/AgRP neurons via Y2 receptors, thereby reducing the release of appetite-stimulating signals. Concurrently, it may indirectly enhance the activity of POMC neurons, leading to increased satiety signaling [1]. PYY also influences brain regions involved in reward processing, potentially reducing the motivation to seek high-fat foods [4]. Additionally, PYY has been shown to cross the blood-brain barrier, allowing it to directly influence central appetite control mechanisms. Some evidence also suggests PYY may increase energy expenditure and fat oxidation rates [5].

GLP-1 Mechanism of Action

GLP-1 acts on GLP-1 receptors (GLP-1R), which are widely distributed throughout the body, including the pancreas, stomach, and various brain regions. In the brain, GLP-1R are found in areas such as the hypothalamus and brainstem, which are critical for appetite regulation. GLP-1 promotes satiety by activating GLP-1R in these brain centers, leading to a reduction in hunger and food intake [3]. A significant mechanism of GLP-1's action is its ability to delay gastric emptying, which slows the rate at which food leaves the stomach and enters the small intestine. This prolonged presence of food in the stomach contributes to a sustained feeling of fullness and reduces the desire to eat more [6]. Furthermore, GLP-1 enhances glucose-dependent insulin secretion and suppresses glucagon release, which helps to stabilize blood sugar levels and prevent post-meal glucose spikes, indirectly contributing to better appetite control.

Key Benefits

Both PYY and GLP-1 offer significant benefits in the context of appetite regulation and metabolic health. Their distinct mechanisms contribute to a comprehensive approach to weight management.

  • Reduced Food Intake and Enhanced Satiety: Both peptides are potent anorexigenic agents, directly leading to a decrease in caloric consumption by promoting feelings of fullness and satisfaction after meals. This is a primary benefit for individuals struggling with overeating or weight gain [1, 3].
  • Weight Loss: By consistently reducing food intake and, in the case of PYY, potentially increasing energy expenditure, both PYY and GLP-1 contribute to significant and sustained weight loss. This is particularly evident with GLP-1 receptor agonists, which are approved for weight management [5, 6].
  • Improved Glycemic Control (GLP-1): GLP-1's role in stimulating insulin secretion and suppressing glucagon makes it highly effective in improving blood glucose levels, especially in individuals with type 2 diabetes. This benefit is crucial for preventing diabetes-related complications [3].
  • Delayed Gastric Emptying (GLP-1): The slowing of gastric emptying by GLP-1 not only enhances satiety but also helps to flatten post-meal glucose excursions, providing a smoother metabolic response to food [6].
  • Modulation of Reward Pathways (PYY): PYY's influence on brain regions involved in reward processing may help reduce cravings and the hedonic drive to consume palatable, high-calorie foods, offering a unique benefit in combating unhealthy eating behaviors [4].
  • Potential for Combination Therapies: The distinct mechanisms of action suggest that combining PYY and GLP-1 therapies could lead to synergistic effects, offering greater weight loss and metabolic improvements than either peptide alone [7].

    • Clinical Evidence

    Numerous studies have investigated the therapeutic potential of PYY and GLP-1 in humans and animal models. Here are some key findings:

    PYY's Effect on Food Intake: A landmark study by Batterham et al. (2003) demonstrated that intravenous infusion of PYY3–36 significantly reduced appetite and 24-hour caloric intake in both lean and obese human subjects. Obese individuals showed similar responsiveness to the anorectic effects of PYY3–36, suggesting its potential as an obesity treatment [8].

    PYY and Gastric Bypass Surgery: Research indicates that bariatric surgeries, particularly Roux-en-Y gastric bypass (RYGBP), lead to significantly elevated postprandial PYY levels. Korner et al. (2006) reported that patients who underwent RYGBP had higher meal-stimulated PYY levels compared to control groups, suggesting PYY plays a role in the sustained weight loss observed after these procedures [9].

    GLP-1 Receptor Agonists for Weight Loss: A meta-analysis by Wilding et al. (2021) on GLP-1 receptor agonists (e.g., semaglutide, liraglutide) for weight management in non-diabetic adults showed significant reductions in body weight compared to placebo. These agents consistently led to substantial weight loss, with some individuals achieving over 15% body weight reduction [10].

    GLP-1 and Satiety: Flint et al. (1998) showed that intravenous infusion of GLP-1 in healthy subjects resulted in a dose-dependent reduction in food intake and increased feelings of satiety. This study provided early evidence for GLP-1's direct role in human appetite regulation [11].

    Combined PYY and GLP-1 Effects: Neary et al. (2005) investigated the co-administration of PYY3–36 and GLP-17–36 in humans and found additive inhibitory effects on food intake. This suggests that targeting both pathways simultaneously could be a more effective strategy for appetite suppression [7].

    Dosing & Protocol

    Peptide YY (PYY):

    Clinical research on PYY dosing for satiety is primarily conducted in experimental settings, often involving intravenous infusions. Typical doses in human studies have ranged from 0.4 pmol/kg/min to 0.9 pmol/kg/min for PYY3–36, administered as a continuous infusion over several hours [8]. These doses are designed to achieve circulating PYY levels comparable to those observed postprandially. For research purposes, single subcutaneous injections have also been explored, but standardized therapeutic protocols for PYY are not yet established for clinical use outside of investigational contexts. The goal is to mimic physiological release patterns to enhance satiety without significant adverse effects.

    Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists:

    GLP-1 receptor agonists are available in various formulations with established dosing protocols for type 2 diabetes and weight management. Dosing typically involves a titration phase to minimize gastrointestinal side effects. Examples include:

    | GLP-1 Agonist | Starting Dose | Maintenance Dose | Administration | Indication (Satiety/Weight Loss) |

    | :------------ | :------------ | :--------------- | :------------- | :------------------------------- |

    | Liraglutide (Saxenda) | 0.6 mg daily | 3.0 mg daily | Subcutaneous | Weight Management |

    | Semaglutide (Wegovy) | 0.25 mg weekly | 2.4 mg weekly | Subcutaneous | Weight Management |

    | Dulaglutide (Trulicity) | 0.75 mg weekly | 4.5 mg weekly | Subcutaneous | Type 2 Diabetes (indirect weight loss) |

    Note: Dosing regimens should always be determined by a healthcare professional based on individual patient needs and response.

    Side Effects & Safety

    Both PYY and GLP-1, while effective, can be associated with side effects, primarily gastrointestinal in nature.

    PYY Side Effects

    Common side effects reported in clinical studies with PYY3–36 infusions include nausea and fullness, particularly at higher doses [12]. These effects are generally transient and dose-dependent. Less common side effects may include abdominal discomfort. Long-term safety data for chronic PYY administration in humans are still emerging, as it is not yet a widely approved therapeutic agent. Some animal studies have suggested potential effects on bone metabolism, but this requires further investigation in humans [13].

    GLP-1 Side Effects

    GLP-1 receptor agonists are well-known for their gastrointestinal side effects, which are often the most common reason for discontinuation. These include:

    Nausea: Very common, especially during dose escalation.

    Vomiting: Common.

    Diarrhea: Common.

    Constipation: Common.

    Abdominal Pain: Common.

    Other less common but serious side effects can include pancreatitis, gallbladder problems (cholelithiasis), and kidney problems. There is also a potential risk of thyroid C-cell tumors (medullary thyroid carcinoma) observed in rodent studies, though this risk has not been confirmed in humans [14]. To mitigate gastrointestinal side effects, GLP-1 RAs are typically started at a low dose and gradually increased over several weeks or months.

    Who Should Consider Peptide YY vs GLP-1?

    The choice between considering PYY (in a research or future therapeutic context) or GLP-1 receptor agonists depends on individual health goals, existing conditions, and risk factors.

    Individuals with Obesity or Overweight: Both peptides are relevant for those seeking significant weight loss. GLP-1 receptor agonists are currently approved and widely used for this purpose, offering a proven path to reduced body weight and improved metabolic markers.

    Individuals with Type 2 Diabetes: GLP-1 receptor agonists are a cornerstone of diabetes management due to their glucose-lowering effects, in addition to their weight loss benefits. PYY's direct impact on glucose control is less pronounced than GLP-1's.

    Those with Impaired Satiety Signals: Individuals who consistently struggle with feeling full after meals, leading to overeating, may benefit from interventions that enhance satiety. Both PYY and GLP-1 address this physiological deficit.

    Patients Post-Bariatric Surgery: Elevated endogenous PYY and GLP-1 levels contribute to the success of bariatric surgery. Understanding these mechanisms can help in managing post-surgical outcomes and potentially identifying adjunctive therapies.

  • Research Participants: PYY is primarily an area of ongoing research. Individuals interested in participating in clinical trials for novel obesity treatments might consider studies involving PYY.

    • Frequently Asked Questions

    Q1: Are PYY and GLP-1 natural hormones?

    A1: Yes, both Peptide YY (PYY) and Glucagon-Like Peptide-1 (GLP-1) are naturally occurring hormones produced by specialized cells (L-cells) in the gastrointestinal tract in response to food intake. They play vital roles in regulating digestion, glucose metabolism, and appetite.

    Q2: Can I get PYY or GLP-1 as a prescription?

    A2: Currently, PYY is not available as a prescription medication for appetite control or weight loss outside of research settings. However, several GLP-1 receptor agonists (e.g., semaglutide, liraglutide) are approved and widely prescribed for the treatment of type 2 diabetes and chronic weight management.

    Q3: What are the main differences in how PYY and GLP-1 work?

    A3: While both promote satiety, PYY primarily acts on Y2 receptors in the brain to inhibit appetite-stimu